ArchiMed’s Acquisition of Stragen Pharma Group

Walder Wyss advised Stragen Pharma and its shareholders in the transaction. Homburger acted as Swiss legal counsel to ArchiMed.

Private equity healthcare fund ArchiMed announced the acquisition of Stragen Pharma from its founder and several shareholders.

Based near Geneva, Switzerland and founded in 1990, Stragen is a developer of hard-to-make, complex generic drugs for the treatment of patients with life-threatening conditions that require comprehensive care and monitoring, usually in intensive care units. Stragen sales of some EUR 70 m in 2020 are growing at a double-digit annual pace. Stragen’s 40 different products are sold in over 60 countries around the world, with a strong European focus.

The Homburger team was led by partner Frank Gerhard (Picture), and comprised lead associate Sarah Chevalley, associate Léonard Aeschlimann Perales and junior associate Alessandra Dumitru (all Corporate / M&A), as well as counsel Peter Müller (Tax).

The Walder Wyss team was led by Fouad G. Sayegh (Partner, Tax) and Patrick W. Vogel (Partner, Corporate/M&A) and included Yacine Rezki (Associate, Tax), Alexander Sorton (Associate, Corporate/M&A), Hugh Reeves (Managing Associate, IP) and Camille Tistounet (Trainee Lawyer).

Involved fees earner: Léonard Aeschlimann Perales – Homburger; Sarah Chevalley – Homburger; Alessandra Dumitru – Homburger; Frank Gerhard – Homburger; Peter Müller – Homburger; Hugh Reeves – Walder Wyss Ltd.; Yacine Rezki – Walder Wyss Ltd.; Fouad Sayegh – Walder Wyss Ltd.; Alexander Sorton – Walder Wyss Ltd.; Camille Tistounet – Walder Wyss Ltd.; Patrick Vogel – Walder Wyss Ltd.;

Law Firms: Homburger; Walder Wyss Ltd.;

Clients: ArchiMed SAS; Stragen Pharma SA;

Author: Federica Tiefenthaler